

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Patent Application of:)	
Karin Ekberg et al.)	Group Art Unit: 1649
)	
Serial No.: 10/575,701)	Examiner: Stacey MacFarlane
)	
Filed: December 11, 2006)	
Title: THERAPEUTIC APPLICATIONS FOR C-PEPTIDE		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION AND STATEMENT

In response to the Notice of Abandonment mailed October 6, 2010, Applicants request consideration of the remarks and arguments contained herein in the above-identified application.

We received Notice of Allowance and Fee(s) due on 06/16/2010 with an expiration date of 09/16/2010.

We then received a Notice To File Corrected Application Papers on 07/14/2010.

We responded on 08/18/2010 with the corrected application papers in the form of a response entitled Amendment Under 37 CFR 1.312 and Response to Notice of Allowance and instructed to pay all fees. Upon receipt of the Notice of Abandonment we immediately contacted Examiner MacFarlane and were advised that the Notice of Abandonment should not have been issued. We considered this matter closed and was awaiting receipt of the original Letters Patent. Upon a review of this matter in PAIR, we realized the application is still showing as abandoned. We then contacted Examiner MacFarlane again and she advised that she would look into the matter. Examiner MacFarlane advised that this matter had been brought to the attention of Supervisor, Jeffrey Stucker (571-272-0911).

We were later advised that our issue fee payment was not accepted because we did not make specific reference to "issue fee" or to "fees due under 37 CFR 1.18", nor did we submit PART B - Fee(s) Transmittal, or its equivalent.

We respectfully request that our Petition For Revival be accepted.

01/25/2011

Date

Global Patent Group, LLC
10411 Clayton Rd., Suite 304
Saint Louis, MO 63131
TEL: 314-567-7788
FAX: 314-567-9595

Respectfully submitted.

/Dennis A. Bennett/

Dennis A. Bennett, Reg. No, 34,547
Attorney for Applicant